PMID- 29204127
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Electronic)
IS  - 1664-0640 (Linking)
VI  - 8
DP  - 2017
TI  - Synthetic Aminoindanes: A Summary of Existing Knowledge.
PG  - 236
LID - 10.3389/fpsyt.2017.00236 [doi]
LID - 236
AB  - OBJECTIVES: Aminoindanes ("bath salts," a class of novel psychoactive substances, 
      NPSs) increased rapidly in popularity on the recreational drug market, 
      particularly after mephedrone and other synthetic cathinones were banned in the 
      UK in 2010. Novel aminoindanes continue to emerge, but relatively little is known 
      about their effects and risks. Their history, chemistry, pharmacology, behavioral 
      effects, pharmacokinetics, and toxicity are reviewed in this paper. METHODS: 
      Scientific literature was searched on ISI Web of Knowledge: Web of Science (WoS) 
      during June and July 2017, using English language terms: aminoindanes such as 
      5,6-methylenedioxy-2-aminoindane (MDAI), 5-iodo-2-aminoindane (5-IAI), 
      2-aminoindane (2-AI), 5,6-methylenedioxy-N-methyl-2-aminoindane (MDMAI), and 
      5-methoxy-6-methyl-2-aminoindane (MMAI). WoS was selected as it searches several 
      databases simultaneously and has quality criteria for inclusion. For typical use 
      and effects, Erowid, PsychonautWiki, Bluelight, and Drugs-Forum were searched; 
      for legal status and epidemiology, the European Information System and Database 
      on New Drugs (EDND) was used. RESULTS: Aminoindanes were first synthesized for 
      medical use, e.g., as anti-Parkinsonian drugs and later as a potential compound 
      facilitating psychotherapy; however, they are now widely substituted for ecstasy. 
      Their mechanisms of action (primarily via serotonin) mean that they may pose a 
      significant risk of serotonin syndrome at high doses or when combined with other 
      drugs. Fatally toxic effects have been observed both in the laboratory in animal 
      studies and in clinic, where deaths related with aminoindanes have been reported. 
      CONCLUSION: Greater knowledge about aminoindanes is urgently required to decrease 
      risks of fatal intoxication, and appropriate legislation is needed to protect 
      public health without impeding research.
FAU - Pinterova, Nikola
AU  - Pinterova N
AD  - National Institute of Mental Health, Klecany, Czechia.
AD  - 3rd Medical Faculty, Charles University, Prague, Czechia.
FAU - Horsley, Rachel R
AU  - Horsley RR
AD  - National Institute of Mental Health, Klecany, Czechia.
FAU - Palenicek, Tomas
AU  - Palenicek T
AD  - National Institute of Mental Health, Klecany, Czechia.
AD  - 3rd Medical Faculty, Charles University, Prague, Czechia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171117
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC5698283
OTO - NOTNLM
OT  - 2-aminoindane
OT  - 5,6-methylenedioxy-2-aminoindane
OT  - 5,6-methylenedioxy-N-methyl-2-aminoindane
OT  - 5-iodo-2-aminoindane
OT  - 5-methoxy-6-methyl-2-aminoindane
OT  - aminoindanes
EDAT- 2017/12/06 06:00
MHDA- 2017/12/06 06:01
PMCR- 2017/11/17
CRDT- 2017/12/06 06:00
PHST- 2017/09/14 00:00 [received]
PHST- 2017/10/31 00:00 [accepted]
PHST- 2017/12/06 06:00 [entrez]
PHST- 2017/12/06 06:00 [pubmed]
PHST- 2017/12/06 06:01 [medline]
PHST- 2017/11/17 00:00 [pmc-release]
AID - 10.3389/fpsyt.2017.00236 [doi]
PST - epublish
SO  - Front Psychiatry. 2017 Nov 17;8:236. doi: 10.3389/fpsyt.2017.00236. eCollection 
      2017.